IRWD Logo

Ironwood Pharmaceuticals, Inc. (IRWD) 

NASDAQ
Market Cap
$537.69M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
203 of 774
Rank in Industry
8 of 47

Largest Insider Buys in Sector

IRWD Stock Price History Chart

IRWD Stock Performance

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain …

Insider Activity of Ironwood Pharmaceuticals, Inc.

Over the last 12 months, insiders at Ironwood Pharmaceuticals, Inc. have bought $160,420 and sold $5.97M worth of Ironwood Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Ironwood Pharmaceuticals, Inc. have bought $7.81M and sold $4.72M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Emany Sravan Kumar (SVP, Chief Financial Officer) — $100,216. Duane Jon R (director) — $60,204.

The last purchase of 6,920 shares for transaction amount of $60,204 was made by Duane Jon R (director) on 2024‑03‑06.

List of Insider Buy and Sell Transactions, Ironwood Pharmaceuticals, Inc.

2024-11-18SaleSVP, COO and CFO
11,001
0.007%
$4.08$44,884-12.87%
2024-11-18SaleSVP, Chief Business Officer
5,360
0.0034%
$4.08$21,869-12.87%
2024-08-12SaleChief Legal Officer
9,910
0.0063%
$4.27$42,316+3.66%
2024-08-12SalePrincipal Accounting Officer
3,107
0.002%
$4.27$13,267+3.66%
2024-06-10Saledirector
22,766
0.0138%
$6.29$143,198-28.75%
2024-06-07Saledirector
35,574
0.0233%
$6.61$235,144-26.61%
2024-06-06Saledirector
44,426
0.0276%
$6.36$282,549-27.75%
2024-05-20SaleChief Executive Officer
67,618
0.0427%
$6.45$436,136-23.68%
2024-05-20SaleCMO,SVP,Head-Res&Drug
16,128
0.0102%
$6.45$104,026-23.68%
2024-05-20SaleChief Legal Officer
17,404
0.011%
$6.45$112,256-23.68%
2024-05-20SaleSVP, Chief Business Officer
22,725
0.0144%
$6.45$146,576-23.68%
2024-03-06Purchasedirector
6,920
0.0045%
$8.70$60,204-27.49%
2024-03-04PurchaseSVP, Chief Financial Officer
10,684
0.0069%
$9.38$100,216-32.40%
2024-02-12SaleChief Executive Officer
177,164
0.1118%
$15.24$2.7M-57.84%
2024-02-12SaleCMO,SVP,Head-Res&Drug
38,618
0.0244%
$15.24$588,538-57.84%
2024-02-12SaleChief Legal Officer
47,380
0.0299%
$15.24$722,071-57.84%
2024-02-12SaleSVP, Chief Business Officer
9,846
0.0062%
$15.24$150,053-57.84%
2024-02-12SalePrincipal Accounting Officer
7,908
0.005%
$15.24$120,518-57.84%
2023-12-14Saledirector
9,926
0.0062%
$11.19$111,072-39.28%
2023-11-20SaleSVP, Chief Business Officer
3,287
0.0022%
$9.69$31,851-16.44%

Insider Historical Profitability

17.79%
Emany Sravan KumarSVP, COO and CFO
309572
0.1934%
$3.3622
Duane Jon Rdirector
121028
0.0756%
$3.3610
DENNER ALEXANDER J
16390000
10.242%
$3.3680+18.72%
Ridgeback Capital Investments L.P.10 percent owner
6842839
4.276%
$3.36342<0.0001%
Hecht Peter MChief Executive Officer
4696917
2.9351%
$3.36116+9.03%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$210.41M15.224.16M-7.01%-$15.87M0.01
The Vanguard Group$170.03M12.2819.52M+21.75%+$30.38M<0.01
Sarissa Capital Management LP$142.76M10.3116.39M0%+$024.97
State Street$121.22M8.7613.92M+20.68%+$20.77M0.01
Pacer Advisors Inc$62.77M4.537.21MNew+$62.77M0.16
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.